Thomas Weisel Ups First Horizon Pharmaceutical

Analyst David Grossman says he upgrades on the company's successful execution in several areas

First Horizon Pharmaceutical (FHRX ) shares rose after the company posted third-quarter EPS of 10 cents, vs. breakeven a year ago, despite 8.8% net revenue decline. It sees 10 cents to 12 cents fourthp-quarter EPS on $26 million to $28 million in revenue.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.